Streetbeat News

Revenues

WEC

Analysts have updated their ratings and price targets for WEC Energy Group (NYSE:WEC), with 7 different analysts offering varied perspectives. The average 12-month price target is now $85.86, down from $88.29. Analyst actions include both downgrades and upgrades, with price targets ranging from $78.00 to $95.00. WEC Energy Group operates in the utility sector, serving customers in several states and owning a stake in American Transmission Co. Despite a recent revenue decline, the company has a strong market position, efficient cost management, and healthy financial metrics such as a high net margin and ROE.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 5:01 pm

CMA

Over the past three months, 12 analysts have provided diverse ratings for Comerica (NYSE:CMA), ranging from bullish to bearish. The average 12-month price target for CMA is $56.12, with a high of $70.50 and a low of $45.00, reflecting a 14.25% increase from the previous target. Analysts from firms like Keefe, Bruyette & Woods, Raymond James, and Goldman Sachs have adjusted their ratings and price targets, responding to market dynamics and Comerica's performance. Comerica, a Dallas-based financial services company, has a lower market cap compared to industry averages and experienced a revenue decline of -9.04% as of September 30, 2023. However, it boasts a high net margin of 27.23% and an ROE of 4.99%, but a lower ROA of 0.28% and a high debt-to-equity ratio of 2.37.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 5:00 pm

BABA

BLK

EWH

MCHI

TCEHY

BlackRock Inc. is selling a Shanghai office complex at a 30% discount due to a sluggish property market. The complex was bought for $167 million in 2018. China's real estate crisis has affected offshore Chinese stocks, with the iShares MSCI Hong Kong Index Fund and the iShares MSCI China ETF both declining by a third of their value, reaching their lowest levels since 2011. Offshore stocks like Tencent and Alibaba have seen substantial declines compared to onshore stocks like Kweichow Moutai and Ping An Insurance.

Portfolio Pulse from Piero Cingari

January 22, 2024 | 4:58 pm

GOOG

GOOGL

AI startup ElevenLabs has achieved a $1.1 billion valuation after raising $80 million in a funding round led by Andreessen Horowitz. The company's voice replication software supports over two dozen languages and is eyed for advertising and media. Concerns over deepfakes are addressed by Alphabet Inc's Google and Universal Music through licensing discussions. ElevenLabs is expanding its technology to media production and monetization of AI voices, while also investing in emotional and intonational enhancements. Greg Brockman of OpenAI launched ChatGPT Voice with five human-like voices.

Portfolio Pulse from Anusuya Lahiri

January 22, 2024 | 4:56 pm

BTCUSD

Morgan Stanley reports that 111 countries are exploring CBDCs, which could challenge the U.S. dollar's global dominance. The report notes CBDCs' potential for innovation in financial services and the shift towards reducing dollar-dependency, fueling interest in digital currencies like Bitcoin, stablecoins, and CBDCs. The geopolitical and economic landscape may prompt a reevaluation of the U.S. stance on CBDCs.

Portfolio Pulse from Murtuza Merchant

January 22, 2024 | 4:18 pm

GYRO

Gyrodyne, LLC (NASDAQ:GYRO) has set January 29, 2024, as the record date for a proposed rights offering aiming to raise $5 million. Shareholders as of this date will receive rights to buy additional shares at $8.00 each. The offering includes a basic subscription privilege and an oversubscription privilege. Proceeds will fund entitlements for Flowerfield and Cortlandt Manor properties, litigation expenses, property negotiations, capital improvements, and general working capital. The offering is pending SEC approval of the Registration Statement.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 4:16 pm

F

The article provides a performance comparison of Ford Motor Co (NYSE:F) against its competitors in the Automobiles industry. It highlights Ford's lower-than-average financial metrics such as P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Ford's market share is expected to increase post-chip shortage, and it operates its combustion engine and BEV businesses separately. The company's high debt-to-equity ratio is noted as a potential risk. The analysis suggests Ford may be undervalued but faces challenges in profitability and growth.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 4:01 pm

PFE

The analysis compares Pfizer (NYSE:PFE) to its competitors in the Pharmaceuticals industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Pfizer's metrics suggest potential undervaluation and lower profitability compared to the industry average. The company's low debt-to-equity ratio indicates a stronger financial position relative to its top 4 peers.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 4:01 pm

ATO

Analyst ratings for Atmos Energy (NYSE:ATO) over the last three months show diverse opinions, with 4 analysts giving ratings ranging from bullish to indifferent. The average 12-month price target has decreased by 2.67% to $118.25, with recent actions including both raised and lowered price targets by analysts from Barclays, Mizuho, and Morgan Stanley. Atmos Energy is a large natural gas utility with a strong market presence but has seen a revenue decline of -18.68% as of September 30, 2023. Despite this, the company maintains a high net margin and ROE, a strong ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 4:00 pm

XNCR

Analysts have recently updated their ratings and price targets for Xencor (NASDAQ:XNCR), with 4 analysts offering opinions ranging from bullish to bearish. The average 12-month price target is now $38.00, down from $43.00, with a high estimate of $50.00 and a low of $32.00. Analysts from Mizuho, Guggenheim, RBC Capital, and Wedbush have all lowered their price targets. Xencor is a clinical-stage biopharmaceutical company with positive revenue growth and strong financial health indicators such as ROE and ROA, but with a revenue growth rate lower than the Health Care sector average.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 4:00 pm